8-K: 4D Molecular Therapeutics Executes Share Exchange for Pre-Funded Warrant with RA Capital

4D Molecular Therapeutics exchanged 535,000 common shares for a pre-funded warrant with RA Capital, exercisable at a nominal price.

Summary

• 4D Molecular Therapeutics, Inc. entered into an exchange agreement with RA Capital Healthcare Fund, L.P. on December 6, 2024.
• Under the agreement, RA Capital exchanged 535,000 shares of 4D Molecular Therapeutics' common stock for a pre-funded warrant.
• The pre-funded warrant allows RA Capital to acquire 535,000 shares of common stock at an exercise price of $0.0001 per share.
• The warrant is exercisable at any time and does not expire until fully exercised.
• The number of shares issuable upon exercise is subject to adjustments for stock dividends, splits, and other similar events.
• A beneficial ownership blocker prevents the holder from exercising the warrant if it would result in ownership exceeding 9.99% of the company's outstanding shares.
• The company issued the pre-funded warrant without registration, relying on an exemption under the Securities Act of 1933.

Sentiment

Score: 7

Explanation: The transaction is a standard financial maneuver, and the terms are typical. It is a positive for the company as it provides potential future capital, but there is a risk of dilution.

Positives

• The exchange provides 4D Molecular Therapeutics with potential future capital through the exercise of the pre-funded warrant.
• The pre-funded warrant structure allows for flexibility in timing of the capital injection.

Risks

• The exercise of the warrant could potentially dilute existing shareholders if the warrant is exercised.
• The 9.99% ownership cap could limit the potential upside for RA Capital.

Future Outlook

The pre-funded warrant provides a mechanism for potential future capital raising for 4D Molecular Therapeutics, contingent on RA Capital's decision to exercise the warrant.

Industry Context

This type of transaction is common in the biotech industry, where companies often use warrants and other equity-linked instruments to raise capital and manage their balance sheets.

Comparison to Industry Standards

• Pre-funded warrants are a common financing tool in the biotech sector, often used by companies with limited revenue to secure funding from institutional investors.
• The exercise price of $0.0001 is typical for pre-funded warrants, as it is designed to be nominal and not a barrier to exercise.
• The 9.99% ownership blocker is a standard provision to prevent the holder from triggering a mandatory filing under Section 13(d) of the Securities Exchange Act.

Stakeholder Impact

• Existing shareholders may experience dilution if the warrant is exercised.
• RA Capital gains the potential to increase its stake in the company.

Next Steps

• RA Capital may exercise the pre-funded warrant at any time.
• 4D Molecular Therapeutics will need to issue shares upon exercise of the warrant.

Key Dates

Keywords

pre-funded warrant, share exchange, RA Capital, equity securities, common stock, beneficial ownership, securities act, exercise price